Trials / Conditions / Corneal Neovascularization

Corneal Neovascularization

24 registered clinical trials studyying Corneal Neovascularization — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. NCT07329686	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1 / Phase 2
Not Yet Recruiting	Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies NCT06412718	IRCCS Ospedale San Raffaele	—
Unknown	Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization. NCT05659940	Zhongshan Ophthalmic Center, Sun Yat-sen University	—
Unknown	The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization NCT05011916	Zhongshan Ophthalmic Center, Sun Yat-sen University	Phase 1 / Phase 2
Recruiting	Corneal Crosslinking for Treatment of Corneal Neovascularization NCT04787471	Price Vision Group	Phase 2 / Phase 3
Unknown	Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic NCT04620109	Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd	Phase 1
Unknown	An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neova NCT04215393	Chengdu Kanghong Biotech Co., Ltd.	Phase 1
Terminated	Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization NCT02797704	Rabin Medical Center	Phase 1 / Phase 2
Withdrawn	Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions NCT02042027	University of Utah	Phase 1
Completed	A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival NCT01996826	Reza Dana, MD	Phase 1 / Phase 2
Terminated	Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea NCT01868360	Balamurali Ambati	Phase 1
Completed	Treatment of Corneal Neovascularization With Topical Pazopanib NCT01257750	Reza Dana, MD	Phase 1 / Phase 2
Completed	Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival NCT01072357	Reza Dana, MD	Phase 1 / Phase 2
Unknown	Bevacizumab for the Treatment of Corneal Neovascularization NCT00992849	Chang Gung Memorial Hospital	Phase 2
Terminated	Topical IL-1-Ra for Treatment of Corneal Neovascularization NCT00915590	Reza Dana, MD	Phase 1 / Phase 2
Completed	Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery NCT00769145	University of Miami	Phase 1
Completed	Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) NCT00681889	Reza Dana, MD	Phase 1
Completed	Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization NCT00512876	Walter Reed Army Medical Center	N/A
Withdrawn	Corneal Thinning During Topical Bevacizumab Therapy NCT00515684	Yonsei University	N/A
Completed	Topical Avastin for Treatment of Corneal Neovascularization NCT00559936	Massachusetts Eye and Ear Infirmary	Phase 1
Completed	Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularizati NCT00555594	Asociación para Evitar la Ceguera en México	Phase 2 / Phase 3
Completed	The Effect of Bevacizumab on Corneal Neovascularization NCT00797303	Instituto de Olhos de Goiania	Phase 4
Completed	Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization NCT00004430	Medical College of Hampton Roads	N/A
Completed	Photodynamic Therapy With Verteporfin for Corneal Neovascularization NCT00471406	Chonnam National University Hospital	N/A